Clinical trial · Interventional
S0344 Intralesional Resection in Treating Patients With Chondrosarcoma of the Bone
A Phase II Surgical Trial Of Intralesional Resection Of Low-Grade Intracompartmental Chondrosarcoma Of Bone
NCT00096213CI-TRIAL-00006072completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Intralesional resection is a less invasive type of surgery for chondrosarcoma of the bone and may have fewer side effects and improve recovery. PURPOSE: This phase II trial is studying how well intralesional resection works in treating patients with low-grade chondrosarcoma of the bone.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Sarcoma | Sarcoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| conventional surgery | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- surgery
- description
- intralesional resection
- interventionNames
- Procedure: conventional surgery
Primary outcomes (1)
- measure
- Probability of local complications
- timeFrame
- two years
Secondary outcomes (2)
- measure
- Probability of local recurrence and development of metastatic disease
- timeFrame
- 5 years
- measure
- Impact of musculoskeletal tumor reconstruction on functional status
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Suspected low-grade intracompartmental chondrosarcoma, as defined by the following criteria:
* Resorption of prior calcifications (indicated by a change in radiographic appearance over time) AND/OR meets at least 2, but no more than 4, of the following criteria:
* Permeative appearance of medullary bone, defined as presence of tumor around 3 sides of a trabecula of normal bone
* Endosteal scalloping, defined as \> 50% of adjacent cortical thickness
* Cortical thickening beyond the thickness of adjacent normal bone
* Bone expansion, defined as a circumferential increase in diameter of the bone beyond the adjacent normal bone
* Positive (i.e., increased uptake or "hot") bone scan
* No cortical disruption and/or soft tissue mass by radiography and CT scan (3 mm cuts are optimal) or MRI
* No presumptive axial (spinal) involvement
* No multifocal disease by bone scan
PATIENT CHARACTERISTICS:
Age
* 18 and over
Performance status
* Not specified
Life expectancy
* Not specified
Hematopoietic
* Not specified
Hepatic
* Not specified
Renal
* Not specified
Other
* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer in complete remission
PRIOR CONCURRENT THERAPY:
Biologic therapy
* No prior biologic therapy for this tumor
Chemotherapy
* No prior chemotherapy for this tumor
Endocrine therapy
* Not specified
Radiotherapy
* No prior radiotherapy for this tumor
Surgery
* No prior surgery for this tumor except biopsy\*
* No concurrent intramedullary fixation NOTE: \*Biopsy is not required
Other
* No prior investigational anticancer agents for this tumorReferences
Publications (0)
Data not yet available
No reference posted for this study.